<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887169</url>
  </required_header>
  <id_info>
    <org_study_id>DC20180338</org_study_id>
    <nct_id>NCT03887169</nct_id>
  </id_info>
  <brief_title>Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.</brief_title>
  <acronym>MetPAP</acronym>
  <official_title>Oral or Enteral Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerance of an oral administration
      of methionine in the treatment of pulmonary alveolar proteinosis due to the double mutation
      Ala393Thr / Ser567Leu in the MARS gene. This disease is very severe and especially leads to
      chronic respiratory insufficiency. There is no curative treatment for this disease. The MARS
      gene encodes the methionine tRNA synthetase (MetRS). Mutations in this gene leads to a defect
      in MetRS function. In cultured mutated yeast, addition of methionine in culture medium
      restores MetRS function. Therefore, we hypothesized that treatment of patients with
      methionine could have beneficial effects on the disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary alveolar proteinosis (PAP) is a rare respiratory disorder. Recently, a genetic
      cause has been identified for a specific form of PAP predominant on La Reunion Island. This
      form is characterized by a multisystem phenotype including PAP, failure to thrive, hepatic
      involvement and chronic inflammation. This is a severe disease without any specific treatment
      and a high rate of mortality related to end-stage respiratory insufficiency. Two recurrent
      mutations were isolated in the MARS gene that encodes the methionine tRNA synthetase (MetRS).
      This enzyme catalyzes the ligation of methionine to tRNA and is critical for protein
      biosynthesis. Functional studies on mutated yeast show an altered growth and protein
      synthesis as compared to control yeast. Addition of methionine in culture medium corrects
      these defects. Complementary experiments on human purified MetRS show altered enzymatic
      catalytic parameters in mutated forms. Increasing blood concentration of methionine in
      patients could correct these parameters and potentially improve patients' phenotype in this
      severe disorder where no curative treatment exists.

      The main objective of this protocol is to determine the tolerance of a prolonged daily
      supplementation of methionine in patients presenting a MARS related PAP. The secondary
      objectives are to determine the efficiency of such treatment on respiratory, hepatic,
      inflammatory and growth status.

      To meet the objectives of the study, enrolled patients will receive daily oral or enteral
      methionine administration at increasing doses, under surveillance of plasma levels of
      methionine and homocysteine, and possible clinical side effects, until determining the
      &quot;ideal&quot; dose for each patient.

      Once daily dosage determined for each patient, this dosage will be continued for a total of 2
      months with daily clinical monitoring of tolerance and bi-monthly plasma levels surveillance
      of methionine and homocysteine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance Assessment</measure>
    <time_frame>From day 0 to day 75</time_frame>
    <description>No adverse event from day 0 to day 75.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate (cycles /min)</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>number of cycles per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen need (L/min)</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>Flow in L/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory signs of struggle</measure>
    <time_frame>At day 0, day 15, day 30, day 45, day 60, day 75</time_frame>
    <description>Presence or absence of signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung lesions</measure>
    <time_frame>At Day 60</time_frame>
    <description>Lesions appearance on thoracic CT scan, scored form 0 to 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipo-proteinaceous material</measure>
    <time_frame>At each bronchial-alveolar washes during the 2,5 months</time_frame>
    <description>Fluid examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>At Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>To evaluate Nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mid upper arm circumference / head circumference rapport</measure>
    <time_frame>At Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>To evaluate Nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatomegaly</measure>
    <time_frame>At Day 0, Day 15, Day 30, Day 45, Day 60, Day 75</time_frame>
    <description>liver damage evaluate by physician during clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholestasis and hepatic cytolysis</measure>
    <time_frame>At Day 0, Day 15, Day 30, Day 60, Day 75</time_frame>
    <description>liver damage evaluate by biological parameters : ASAT, ALAT, GGT, PAL, Bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatomegaly</measure>
    <time_frame>At Day 0 and Day 60</time_frame>
    <description>liver damage evaluate by echography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedimentation rate</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G level</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate Systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemoglobin level</measure>
    <time_frame>At Day 0, Day 30, Day 60</time_frame>
    <description>Biological parameters to evaluate inflammatory anaemia</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Pulmonary Alveolar Proteinosis</condition>
  <condition>Mutation Ala393Thr of the MARS Gene</condition>
  <condition>mutationSer567Leu of the MARS Gene</condition>
  <arm_group>
    <arm_group_label>Methionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methionine</intervention_name>
    <description>Administration of methionine from D1 to D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12, B9, B6, C supplementation</intervention_name>
    <description>In case of hyperhomocysteinemia</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Methionine/homocysteine Dosage</intervention_name>
    <description>Plasma concentration control of methionine and homocysteine from D0 to D75</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Thoracic CT scan</intervention_name>
    <description>At D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Abdominal and liver ultrasound.</intervention_name>
    <description>At D60</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Brain MRI</intervention_name>
    <description>In case of abnormal neurological examination</description>
    <arm_group_label>Methionine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minor Patient under the age of 10 with alveolar proteinosis by double mutation
             Ala393Thr and SER567LEU of the MARS gene, genetically proven.

          -  Patient in need of prolonged hospitalization in Necker for treatment of
             bronchial-alveolar washes in the context of care.

          -  Patient for which methionine can be administered orally or by enteral probe
             (Nasogastric or gastrostomy probe)

          -  Signed Informed consent form by parents / legal guardian

        Exclusion Criteria:

          -  Patient with alveolar proteinosis by other mutations of the MARS gene

          -  Patient with alveolar proteinosis secondary to another etiology or without identified
             cause

          -  Refusal to participate in the study

          -  High blood pressure requiring drug treatment

          -  Heart failure

          -  Known hypersensitivity to one of the substances used or potentially used in the study:
             methionine, vitamins B6, B12, B9 and C

          -  Pre-Hypermethioninemia (Methioninemia &gt; + 2 DS of normal for age) whatever the cause
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice HADCHOUEL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Necker Enfants Malades</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice HADCHOUEL, PhD</last_name>
    <phone>+ 33 1 44 49 48 47</phone>
    <email>alice.hadchouel-duverge@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie Henry, Master</last_name>
    <phone>+33 1 44 49 56 66</phone>
    <email>elodie.henry@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alice HADCHOUEL, PhD</last_name>
      <phone>+ 33 1 44 49 48 47</phone>
      <email>alice.hadchouel-duverge@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary alveolar proteinosis</keyword>
  <keyword>MARS gene</keyword>
  <keyword>methionine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

